Haemonetics Co. (NYSE:HAE) Shares Purchased by Rhumbline Advisers

Rhumbline Advisers boosted its position in shares of Haemonetics Co. (NYSE:HAEFree Report) by 0.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 162,933 shares of the medical instruments supplier’s stock after purchasing an additional 1,118 shares during the period. Rhumbline Advisers owned 0.32% of Haemonetics worth $14,596,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in HAE. Group One Trading L.P. acquired a new stake in Haemonetics during the third quarter valued at approximately $55,000. Arjuna Capital boosted its holdings in Haemonetics by 1.6% during the third quarter. Arjuna Capital now owns 21,004 shares of the medical instruments supplier’s stock valued at $1,882,000 after purchasing an additional 326 shares in the last quarter. Essex Investment Management Co. LLC boosted its holdings in Haemonetics by 12.1% during the third quarter. Essex Investment Management Co. LLC now owns 11,208 shares of the medical instruments supplier’s stock valued at $1,004,000 after purchasing an additional 1,208 shares in the last quarter. Jupiter Asset Management Ltd. boosted its holdings in Haemonetics by 12.3% during the third quarter. Jupiter Asset Management Ltd. now owns 11,624 shares of the medical instruments supplier’s stock valued at $1,041,000 after purchasing an additional 1,274 shares in the last quarter. Finally, Chase Investment Counsel Corp acquired a new stake in Haemonetics during the third quarter valued at approximately $1,681,000. 99.38% of the stock is owned by institutional investors and hedge funds.

Haemonetics Stock Up 2.2 %

Shares of HAE opened at $74.90 on Friday. The company has a market capitalization of $3.80 billion, a P/E ratio of 30.45, a PEG ratio of 1.81 and a beta of 0.34. The company has a debt-to-equity ratio of 0.91, a current ratio of 2.92 and a quick ratio of 1.76. Haemonetics Co. has a one year low of $70.74 and a one year high of $95.26. The business’s 50 day simple moving average is $80.99 and its 200-day simple moving average is $85.30.

Haemonetics (NYSE:HAEGet Free Report) last announced its earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 EPS for the quarter, topping the consensus estimate of $0.94 by $0.10. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. The business had revenue of $336.20 million for the quarter, compared to the consensus estimate of $320.84 million. During the same period in the previous year, the business earned $0.85 EPS. Haemonetics’s revenue was up 10.1% compared to the same quarter last year. As a group, sell-side analysts predict that Haemonetics Co. will post 3.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on HAE. StockNews.com downgraded Haemonetics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 16th. Barrington Research reissued an “outperform” rating and issued a $105.00 target price on shares of Haemonetics in a report on Tuesday, February 13th.

Get Our Latest Report on HAE

Haemonetics Profile

(Free Report)

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.

Featured Articles

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.